Log In
Print this Print this

anti-CA9 ADC (BAY 79-4620)

  Manage Alerts
Collapse Summary General Information
Company Bayer AG
DescriptionHuCaL derived antibody-drug conjugate (ADC) targeting CA IX
Molecular Target Carbonic anhydrase IX (CAIX)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
PartnerSeattle Genetics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today